Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.

Gates MA, Tworoger SS, Terry KL, De Vivo I, Hunter DJ, Hankinson SE, Cramer DW.

Int J Cancer. 2009 Feb 1;124(3):729-33. doi: 10.1002/ijc.23924.

2.

Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population.

Jara L, Gonzalez-Hormazabal P, Cerceño K, Di Capua GA, Reyes JM, Blanco R, Bravo T, Peralta O, Gomez F, Waugh E, Margarit S, Ibañez G, Romero C, Pakomio J, Roizen G.

Breast Cancer Res Treat. 2013 Jan;137(2):559-69. doi: 10.1007/s10549-012-2359-z. Epub 2012 Dec 7.

PMID:
23225170
3.

Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.

Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Wijers-Koster PM, Blom JC, Pooley KA, Klijn JG, Tollenaar RA, Devilee P, van Asperen CJ.

Breast Cancer Res. 2007;9(6):R78.

4.

Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.

Shan J, Mahfoudh W, Dsouza SP, Hassen E, Bouaouina N, Abdelhak S, Benhadjayed A, Memmi H, Mathew RA, Aigha II, Gabbouj S, Remadi Y, Chouchane L.

Breast Cancer Res Treat. 2012 Oct;135(3):715-24. doi: 10.1007/s10549-012-2202-6. Epub 2012 Aug 22.

5.

A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India.

Siddiqui S, Chattopadhyay S, Akhtar MS, Najm MZ, Deo SV, Shukla NK, Husain SA.

PLoS One. 2014 Oct 21;9(10):e110426. doi: 10.1371/journal.pone.0110426. eCollection 2014.

6.

Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.

Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K, von Smitten K, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengström M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X; Australian Ovarian Cancer Management Group; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Klijn JG, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD.

PLoS Genet. 2008 Apr 25;4(4):e1000054. doi: 10.1371/journal.pgen.1000054.

7.

Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.

Andersen SW, Trentham-Dietz A, Figueroa JD, Titus LJ, Cai Q, Long J, Hampton JM, Egan KM, Newcomb PA.

Menopause. 2013 Mar;20(3):354-8. doi: 10.1097/GME.0b013e318268ca46.

8.

Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women.

Gorodnova TV, Kuligina ESh, Yanus GA, Katanugina AS, Abysheva SN, Togo AV, Imyanitov EN.

Cancer Genet Cytogenet. 2010 May;199(1):69-72. doi: 10.1016/j.cancergencyto.2010.01.020. No abstract available.

PMID:
20417875
9.

Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.

Rebbeck TR, DeMichele A, Tran TV, Panossian S, Bunin GR, Troxel AB, Strom BL.

Carcinogenesis. 2009 Feb;30(2):269-74. doi: 10.1093/carcin/bgn247. Epub 2008 Nov 20.

10.

Genome-wide association study identifies novel breast cancer susceptibility loci.

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R; SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schürmann P, Dörk T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X; kConFab; AOCS Management Group, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA.

Nature. 2007 Jun 28;447(7148):1087-93.

11.

Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States.

Slattery ML, Baumgartner KB, Giuliano AR, Byers T, Herrick JS, Wolff RK.

Breast Cancer Res Treat. 2011 Sep;129(2):531-9. doi: 10.1007/s10549-011-1498-y. Epub 2011 Apr 8.

12.

Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population.

Chan M, Ji SM, Liaw CS, Yap YS, Law HY, Yoon CS, Wong CY, Yong WS, Wong NS, Ng R, Ong KW, Madhukumar P, Oey CL, Tan PH, Li HH, Ang P, Ho GH, Lee AS.

Breast Cancer Res Treat. 2012 Nov;136(1):209-20. doi: 10.1007/s10549-012-2234-y. Epub 2012 Sep 11.

PMID:
22965832
13.

Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer.

Jia C, Cai Y, Ma Y, Fu D.

Breast Cancer Res Treat. 2010 Nov;124(2):521-8. doi: 10.1007/s10549-010-0872-5. Epub 2010 Apr 4. Erratum in: Breast Cancer Res Treat. 2010 Nov;124(2):529. Jia, Chenyou [corrected to Jia, Chengyou].

PMID:
20364400
14.

Breast cancer susceptibility variants alter risks in familial disease.

Latif A, Hadfield KD, Roberts SA, Shenton A, Lalloo F, Black GC, Howell A, Evans DG, Newman WG.

J Med Genet. 2010 Feb;47(2):126-31. doi: 10.1136/jmg.2009.067256. Epub 2009 Jul 16.

PMID:
19617217
15.

FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors.

Marian C, Ochs-Balcom HM, Nie J, Kallakury BV, Ambrosone CB, Trevisan M, Edge S, Shields PG, Freudenheim JL.

Int J Cancer. 2011 Aug 1;129(3):702-12. doi: 10.1002/ijc.25686. Epub 2010 Nov 12.

16.

Association between rs2981582 polymorphism in the FGFR2 gene and the risk of breast cancer in Mexican women.

Murillo-Zamora E, Moreno-Macías H, Ziv E, Romieu I, Lazcano-Ponce E, Angeles-Llerenas A, Pérez-Rodríguez E, Vidal-Millán S, Fejerman L, Torres-Mejía G.

Arch Med Res. 2013 Aug;44(6):459-66. doi: 10.1016/j.arcmed.2013.08.006. Epub 2013 Sep 18.

17.

Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.

Travis RC, Reeves GK, Green J, Bull D, Tipper SJ, Baker K, Beral V, Peto R, Bell J, Zelenika D, Lathrop M; Million Women Study Collaborators.

Lancet. 2010 Jun 19;375(9732):2143-51. doi: 10.1016/S0140-6736(10)60636-8. Epub 2010 Jun 3. Erratum in: Lancet. 2010 Jun 19;375(9732):2142.

18.

Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients.

Hemminki K, Müller-Myhsok B, Lichtner P, Engel C, Chen B, Burwinkel B, Försti A, Sutter C, Wappenschmidt B, Hellebrand H, Illig T, Arnold N, Niederacher D, Dworniczak B, Deissler H, Kast K, Gadzicki D, Meitinger T, Wichmann HE, Kiechle M, Bartram CR, Schmutzler RK, Meindl A.

Int J Cancer. 2010 Jun 15;126(12):2858-62. doi: 10.1002/ijc.24986.

19.

An investigation of the effects of FGFR2 and B7-H4 polymorphisms in breast cancer.

Ozgöz A, Samli H, Oztürk KH, Orhan B, Icduygu FM, Aktepe F, Imirzalioglu N.

J Cancer Res Ther. 2013 Jul-Sep;9(3):370-5. doi: 10.4103/0973-1482.114434.

20.

Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study.

Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, Lynch CF, Malone KE, Stovall M, Capanu M, Liang X, Smith SA, Mychaleckyj J, Hou X, Mellemkjaer L, Boice JD Jr, Siniard A, Duggan D, Thomas DC; WECARE Study Collaborative Group, Concannon P.

Breast Cancer Res. 2011;13(6):R114. doi: 10.1186/bcr3057. Epub 2011 Nov 17.

Items per page

Supplemental Content

Write to the Help Desk